Scopus Publication Detail
The publication detail shows the title, authors (with indicators showing other profiled authors), information on the publishing organization, abstract and a link to the article in Scopus. This abstract is what is used to create the fingerprint of the publication.
Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors
Jesper B. Andersen; Bart Spee; Boris R. Blechacz; Itzhak Avital; Mina Komuta; Andrew Barbour; Elizabeth A. Conner; Matthew C. Gillen; Tania Roskams; Lewis R. Roberts; et al. (Profiled Author: Boris Blechacz)
Background & Aims: Cholangiocarcinoma is a heterogeneous disease with a poor outcome that accounts for 5%-10% of primary liver cancers. We characterized its genomic and genetic features and associated these with patient responses to therapy. Methods: We profiled the transcriptomes from 104 surgically resected cholangiocarcinoma samples collected from patients in Australia, Europe, and the United States; epithelial and stromal compartments from 23 tumors were laser capture microdissected. We analyzed mutations in KRAS, epidermal growth factor receptor (EGFR), and BRAF in samples from 69 tumors. Changes in gene expression were validated by immunoblotting and immunohistochemistry; integrative genomics combined data from the patients with data from 7 human cholangiocarcinoma cell lines, which were then exposed to trastuzumab and lapatinib. Results: Patients were classified into 2 subclasses, based on 5-year survival rate (72% vs 30%; χ 2 = 11.61; P <.0007), time to recurrence (13.7 vs 22.7 months; P <.001), and the absence or presence of KRAS mutations (24.6%), respectively. Class comparison identified 4 survival subgroups (SGIIV; χ 2 = 8.34; P <.03); SGIII was characterized by genes associated with proteasomal activity and the worst prognosis. The tumor epithelium was defined by deregulation of the HER2 network and frequent overexpression of EGFR, the hepatocyte growth factor receptor (MET), pRPS6, and Ki67, whereas stroma was enriched in inflammatory cytokines. Lapatinib, an inhibitor of HER2 and EGFR, was more effective in inhibiting growth of cholangiocarcinoma cell lines than trastuzumab. Conclusions: We provide insight into the pathogenesis of cholangiocarcinoma and identify previously unrecognized subclasses of patients, based on KRAS mutations and increased levels of EGFR and HER2 signaling, who might benefit from dual-target tyrosine kinase inhibitors. The group of patients with the worst prognosis was characterized by transcriptional enrichment of genes that regulate proteasome activity, indicating new therapeutic targets. © 2012 AGA Institute.
PMID: 22178589 PMCID: PMC3413201
This section shows information related to the publication - computed using the fingerprint of the publication - including related publications, related experts with fingerprints representing significant amounts of overlap between their fingerprint and this publication. The red dots indicate whether those experts or terms appear within the publication, thereby showing potential and actual connections.
Masahiro Fukuoka; Yi-Long Wu; Sumitra Thongprasert; Patrapim Sunpaweravong; Swan-Swan Leong; Virote Sriuranpong; Tsu-Yi Chao; Kazuhiko Nakagawa; Da-Tong Chu; Nagahiro Saijo; et al.
Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non - small-cell lung cancer in Asia (IPASS)Journal of Clinical Oncology. 2011;29(21):2866-2874.
John J. Tentler; Sujatha Nallapareddy; Aik Choon Tan; Anna Spreafico; Todd M. Pitts; M. Pia Morelli; Heather M. Selby; Maria I. Kachaeva; Sara A. Flanigan; Gillian N. Kulikowski; et al.Molecular Cancer Therapeutics. 2010;9(12):3351-3362.
Jeonghee Cho; Sandra Pastorino; Qing Zeng; Xiaoyin Xu; William Johnson; Scott Vandenberg; Roel Verhaak; Andrew D. Cherniack; Hideo Watanabe; Amit Dutt; et al.Cancer Research. 2011;71(24):7587-7596.
Appears in this Document